profit from every $100 of sales.
$0$100
Haleon
$9.17+0.88% today
-4.6% in 1 year
1-year low $8.571-year high $11.27
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $18.28 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Haleon sold, what it kept, and what it did with the cash.
Sales went from £10.9 billion in 2022 to £11.0 billion in 2025, with £1.67 billion of profit last year.
SalesProfit
Haleon handed back 57% of the cash it generated last year.
Buybacks £654M£612M
Free cash flow 2025£2.2B
Bought back its own shares£654M
Paid as dividends£612M
Cash vs. debt£1.3B vs. £8.6B
Haleon vs. similar companies
Haleon grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Haleon | 18.3× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Haleon's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10,858 | 11,302 | 11,233 | 11,030 | |
| 6,577 | 6,747 | 6,824 | 7,080 | |
| 1,825 | 1,996 | 2,206 | 2,412 | |
| 2,183 | 2,351 | 2,628 | 2,859 | |
| 1,060 | 1,049 | 1,442 | 1,667 | |
| 0.23 | 0.23 | 0.31 | 0.37 | |
| 60.6% | 59.7% | 60.7% | 64.2% | |
| 16.8% | 17.7% | 19.6% | 21.9% | |
| 9.8% | 9.3% | 12.8% | 15.1% |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 34,815 | 34,055 | 34,315 | 32,630 |
| Cash | 606 | 994 | 2,195 | 1,260 |
| Total debt | 10,440 | 9,431 | 10,102 | 8,584 |
| Total liabilities | 18,358 | 17,326 | 18,091 | 16,146 |
| 16,331 | 16,606 | 16,166 | 16,425 | |
| 4,618 | 4,642 | 4,592 | 4,513 | |
| 5.6% | 6.2% | 6.9% | 7.9% | |
| 6.5% | 6.3% | 8.9% | 10.1% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,063 | 2,100 | 2,301 | 2,634 | |
| 328 | 336 | 318 | 413 | |
| 1,735 | 1,764 | 1,983 | 2,221 | |
| Dividends paid | 2,682 | 388 | 570 | 612 |
| 0 | 0 | 619 | 654 | |
| 15 | 76 | 102 | 86 |
Valuation
- 18.3×
- 21.7×
- 1.06
- 1.8×
- 2.8×
- 13.7×
- 13.2×
- 7.3%
- 5.5%
- 2.2%
Profitability
- 64.2%
- 21.9%
- 15.1%
- 25.2%
- 8.1%
- 6.8%
- 6.4%
- 3.2%
- 5.6%
- 2.8%
Growth
- +0.5%
- +17.2%
- −3.9%
- –
- −0.8%
Financial health
- 2.6×
- 0.52
- 26.3%
- 7.2×
- 0.92
- 0.71
- 0.25
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 37%of 946
Top 20%of 872
Top 27%of 563
Bottom 17%of 868
Top 11%of 986
What analysts expect
- Average price target
- $10.20
- Range
- $10.20 – $10.20
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 25, 2026 | 0.26 | 0.25 | +3.4% |
| Oct 30, 2025 | 0.14 | 0.24 | −42.8% |
| Aug 7, 2025 | 0.08 | 0.24 | −67.3% |
| Feb 27, 2025 | 0.05 | 25.25 | −99.8% |
| Oct 31, 2024 | 0.14 | 0.11 | +27.3% |
| May 1, 2024 | 0.12 | 0.11 | +9.1% |
| Feb 29, 2024 | 6.54 | 10.27 | −36.3% |
| Aug 2, 2023 | 0.08 | 0.22 | −63.5% |
2.2%of the share price, paid each year
On $1,000 invested$22a year at today's yield, before tax
–per share
Raised2 yearsin a row, in our data
Paid per share, each year
$0.10 in 2023 → $0.18 in 2025
How safe it looks
36.7% of its profit
Room to growStretchedMore than it earns: 27.6%
News
Haleon And 2 British AI Healthcare Stocks To WatchYahoo Finance · Oct 18, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
58No pass
Benjamin Graham
61Pass
Philip Fisher
68Pass
Peter Lynch
61Pass
Joel Greenblatt
34No pass
Charlie Munger
48No pass
Terry Smith
47No pass
Questions about Haleon
Is Haleon a good stock to buy?
A solid business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Haleon AI analysis
What does Haleon do?
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It is in Drug Manufacturers - Specialty & Generic, based in Weybridge, United Kingdom, with 24,535 employees.
Does Haleon pay a dividend?
Yes. At today's price the dividend is 2.2% a year, about 37% of its yearly profit. In 2025 it paid out $612 million in dividends.
Is Haleon stock halal?
Yes. Haleon passes our halal screen: its business is permitted and its debt is 28% of its market value, under the 30% limit. How we check
How has Haleon stock done over the past year?
Down 4.6% over the past twelve months, to $9.17. It traded between $8.57 and $11.27 and is 18.6% below its high.
Who are Haleon's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Haleon's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.